Neurocrine Biosciences Inc. presented new findings from a one-year clinical study at the Endocrine Society’s 2025 Annual Meeting, showing that CRENESSITY can lead to weight reduction and improved insulin resistance in patients with classic congenital adrenal hyperplasia. Phase 3 CAHtalyst trials indicate that the drug could have positive long-term health impacts for those with the condition. Chief Medical Officer, Sanjay Keswani, emphasized the potential of CRENESSITY to improve cardiometabolic outcomes and change the standard of care for classic congenital adrenal hyperplasia. Additional health news can be found on rttnews.com.

Read more at Nasdaq, Inc.: NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients